Glycopyrrolate inhaled - Pearl Therapeutics

Drug Profile

Glycopyrrolate inhaled - Pearl Therapeutics

Alternative Names: GP MDI; PT-001; PT001 GP

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 01 Nov 2016 Phase-III clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in Belgium (Inhalation) (NCT02937584; EudraCT2015-001744-11)
  • 01 Apr 2015 Phase-II clinical trials in Asthma in USA (Inhalation) (NCT02433834)
  • 01 Mar 2015 Pearl Therapeutics completes the PINNACLE 3 trial in Chronic obstructive pulmonary disease in USA, Australia and New Zealand (NCT01970878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top